Jonathan Alspaugh is President and CFO of Spyre Therapeutics Inc.
Person profile
Latest filings (excl ownership)
No filings
Latest ownership filings
4
Aeglea BioTherapeutics, Inc.
30 Jun 23
4
Aeglea BioTherapeutics, Inc.
24 Feb 23
4
Aeglea BioTherapeutics, Inc.
25 Aug 22
4
Aeglea BioTherapeutics, Inc.
15 Mar 22
4
Aeglea BioTherapeutics, Inc.
22 Feb 22
4
Aeglea BioTherapeutics, Inc.
13 Dec 21
4
Aeglea BioTherapeutics, Inc.
18 Aug 21
4
Aeglea BioTherapeutics, Inc.
8 Jul 21
3
Aeglea BioTherapeutics, Inc.
8 Jul 21
Recent insider trades
Date | Company | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
22 Jun 23 | SYRE Spyre Therapeutics | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 0.3 | 19,787,969 | 5.94 mm | 19,787,969 |
23 Feb 23 | SYRE Spyre Therapeutics | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 0.44 | 640,000 | 281.60 k | 640,000 |